CorNeat Vision: Scaling Biomimetics for Ophthalmology and More

article image

With a platform based on a proprietary, nondegradable biomimetic material, CorNeat Vision has the opportunity to treat many diseases. It begins where the need is greatest, by providing an artificial cornea to patients for whom corneal transplantation has failed or is contraindicated.

CorNeat Visionis in the business of pushing boundaries. The lean Israeli company of only 15 full-time employees was founded five years ago to develop a patented, nondegradable biomimetic material for permanent integration with native tissue. The material, which closely mimics the collagen skeleton of natural tissue, can provide soft-tissue reinforcement, membrane formation, and more. “One of the key distinguishing features of CorNeat Vision’s approach is our emphasis on optimizing and fabricating permanent synthetic structures,” says CEO and VP of Research and Development Almog Aley-Raz, a seasoned hi-tech entrepreneur and engineer by background.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: